In other words, current study suggests that combination chemotherapy with HIF-1a inhibition would target the normoxic bladder cancer cells, which may help to optimize conventional chemotherapy with HIF-1 inhibitors. The gene discussed is HIF1A; the disease is urinary bladder carcinoma.